Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high22.000 31/05/16
52 week low15.000 22/03/17
52 week change -4.750 (-23.17%)
4 week volume2,939,537 24/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Hardman Research: Addressing woundcare in the US

RNS Number: 1719Z Tissue Regenix Group PLC 13 March 2017 Hardman Research: Addressing woundcare in the US Addressing woundcare in the US: TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have continued to ga...

Innovative Technology Contract Awarded

RNS Number: 1394Y Tissue Regenix Group PLC 01 March 2017 Tissue Regenix Group plc Innovative Technology Contract Awarded DermaPure Receives Innovative Technology Contract from Vizient, Inc. Leeds, 01 March 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces effective from...

TRX says DermaPure added to Federal Supply Schedule

Tissue Regenix Group has been included on the US Department of Veteran Affairs (VA) Federal Supply Schedule (FSS) vi...

DermaPure? added to the Federal Supply Schedule

RNS Number: 8102V Tissue Regenix Group PLC 02 February 2017 Tissue Regenix Group plc DermaPure added to the Federal Supply Schedule Leeds, 02 February 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces DermaPure a decellularized dermal allograft, utilising Tissue Regen...

Tissue Regenix appoints Paul Devlin as group FD

Tissue Regenix Group announces the appointment of Paul Devlin as Group Finance Director and Company Secretary with...

Directorate Change

RNS Number: 4867T Tissue Regenix Group PLC 06 January 2017 Tissue Regenix Group plc Appointment of Group Finance Director Leeds, 06 January 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announce the appointment of Paul Devlin as Group Finance Director and Company Secret...

Hardman Research: a/c change: Not simply 11/12ths

RNS Number: 3576R Tissue Regenix Group PLC 09 December 2016 Hardman Research: a/c change: Not simply 11/12ths Accounting period change: Not simply 11/12ths: TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have ...

TR1- NOTIFICATION OF MAJOR INTEREST IN SHARES

RNS Number: 2174R Tissue Regenix Group PLC 07 December 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Tissue Regenix Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting ri...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

hardman & co
Tissue Regenix Group Plc
17/03/2017
TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have...
edison investment research
Tissue Regenix Group Plc
03/02/2017
Edison Investment Research is terminating coverage on Tissue Regenix Group (TRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...
edison investment research
Tissue Regenix Group Plc
19/10/2016
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound...

Latest discussion posts More

  • Re: RNS Hardman Research

    Yes, CL, it looks like a few others have taken the same view, hence the recent weakness in the sp. I'm holding for now, and may buy more if it drops further. The ...
    20-Mar-2017
    theprior
  • Re: RNS Hardman Research

    Thought this was a positive note on where TRX is now. Lots of pluses. I was bit thrown by the lack of near future potential profit or move into profit from all the increase in ...
    13-Mar-2017
    Chicken Lips
  • RNS Hardman Research

    Interesting to note wider expansion of product availability across different sectors and projections of future ...
    13-Mar-2017
    theprior

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.32%
TESCO23%
BP23%
SIRIUS MINERALS22%
TAYLOR WIMPEY18%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX